Bedinvetmab (Librela) Adverse Events in Dogs: Neurological Safety Profile

Bottom line

• Librela (bedinvetmab injection) is an anti-NGF canine monoclonal antibody approved for control of osteoarthritis pain in dogs; the 2025 updated FDA label lists neurological adverse events — including ataxia, seizures, paresis, proprioception deficits, and paralysis — in the post-approval experience section.[1]
• As of the April 2026 openFDA data cut, 17,911 adverse event reports have been submitted for bedinvetmab (NADA 141-562), making it one of the most-reported veterinary drugs in the FDA adverse event system.[2]
• The FDA label (January 2025) explicitly notes that in some cases death, including euthanasia, has been reported as an outcome of the listed adverse events.[1]
• The label includes a precaution regarding concurrent NSAID use: the safety of anti-NGF monoclonal antibodies with NSAIDs has not been established in dogs, and rapidly progressing osteoarthritis (RPOA) has been reported in a small number of human patients receiving anti-NGF therapy alongside long-term NSAIDs.[1]
• Controlled field studies demonstrated efficacy (EU study: 45.2% vs 17.0% treatment success at Day 28, P=0.0018); effectiveness is achieved after a minimum of two monthly doses.[1]

Drug facts

• Class: Canine anti-nerve growth factor (anti-NGF) monoclonal antibody; IgG class
• Mechanism: Binds NGF, reduces NGF binding to TrkA and p75NTR receptors, decreases TrkA signal transduction in pain pathways (per the label)[1]
• Route/interval: Subcutaneous injection; once monthly; FDA-approved at a minimum of 0.5 mg/kg body weight (per the label dosing table)[1]
• Indication: Control of pain associated with osteoarthritis in dogs[1]
• Approval: FDA NADA 141-562, first marketed July 2023; label updated January 2025[1]
• Label contraindications: Known hypersensitivity to bedinvetmab; breeding, pregnant, or lactating dogs[1]
• Label common AEs (field studies): UTI 11.1% vs 8.0% control (US study); increased BUN 13.8% vs 4.9% control (EU study)[1]
• Post-approval AEs (2025 label): ataxia, seizures, paresis, proprioception deficits, paralysis; polydipsia, polyuria/pollakiuria, urinary incontinence; vomiting, diarrhea; muscle weakness, muscle tremors, lameness; anorexia, lethargy, recumbency; death/euthanasia reported[1]

A specific patient on Librela?

Get an instant cited answer — no signup needed for your first question. Voyage Clinical Desk brings species-specific dose math, monitoring plans, and peer-reviewed evidence to the case in front of you.

Try Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=bedinvetmab-librela-adverse-events-dogs

What the evidence shows

Efficacy: what the controlled field studies demonstrated

Two masked, randomized, controlled 84-day field studies underpin the Librela approval. The US study enrolled 272 client-owned dogs with OA confirmed by radiography and orthopedic examination (135 Librela, 137 saline control)[1][3]; the EU study enrolled 287 dogs at 26 sites across Portugal, Hungary, Ireland, and Germany (138 Librela, 143 control).[1][4]

The primary endpoint was treatment success at Day 28, defined as a reduction of at least 2 points in Pain Interference Score and at least 1 point in Pain Severity Score on the Canine Brief Pain Inventory. In the US study, the success rates were 48.0% (Librela) versus 36.1% (control); this difference did not reach statistical significance at Day 28, but the treatment effect was significant at Days 42 through 84. In the EU study, the success rates were 45.2% (Librela) versus 17.0% (control), which was statistically significant (P=0.0018).[1]

Both studies demonstrated that treatment effect built with subsequent doses. Success rates in the Librela groups continued to improve from Day 42 onward, reaching approximately 57% at Day 84 in the US study and approximately 50% in the EU study. The label states that effectiveness may not be achieved until after the second dose.[1]

Pharmacokinetics: what practitioners need to know

After subcutaneous administration, peak serum concentrations occur at 4 to 7 days. Mean bioavailability relative to intravenous dosing is approximately 86%. In laboratory pharmacokinetic studies, the elimination half-life was approximately 12 days; in field-study dogs with osteoarthritis, the half-life was highly variable and averaged approximately 19 days (harmonic mean 15.8 days). Steady-state is achieved after approximately two doses.[1]

Bedinvetmab is expected to be degraded into small peptides and amino acids via catabolic pathways in a manner similar to endogenous IgG; the metabolic pathway has not been formally characterized.[1]

Post-approval neurological adverse event profile

The FDA label was updated in January 2025 to include a post-approval experience section that had not appeared in the original approval. The section explicitly lists, in decreasing order of reporting frequency within the neurological body system: ataxia, seizures, paresis, proprioception deficits, paralysis. General adverse events listed include anorexia, lethargy, and recumbency. The label states that in some cases death, including euthanasia, has been reported as an outcome.[1]

The openFDA adverse event database confirms the breadth of neurological reports. As of the April 2026 data cut, 17,911 adverse event reports have been submitted for bedinvetmab.[2] Recent reports in the database include cases featuring proprioception deficit, lumbar pain, falling, difficulty to rise, ataxia, trembling, urinary incontinence, seizures, gait abnormality, lateral recumbency, and unresponsiveness to stimuli in dogs of various breeds, ages, and weights.[2] The reports are submitted by veterinarians and other healthcare professionals and represent spontaneous pharmacovigilance data; causal attribution for individual cases is not established from this dataset alone.

Precautions: NSAID co-administration and cardiac disease

The label includes a specific precaution regarding concurrent NSAID use: "The safe use of anti-NGF monoclonal antibodies with concurrent nonsteroidal anti-inflammatory drugs (NSAIDs) has not been established in dogs. In human clinical trials, rapidly progressing osteoarthritis (RPOA) has been reported in a small number of patients receiving humanized anti-NGF monoclonal antibody therapy. The incidence of these events increased in human patients receiving NSAID treatment long term in combination with an anti-NGF monoclonal antibody. RPOA has not been characterized or reported in dogs."[1] A limited two-week laboratory co-administration study was conducted but did not provide sufficient data to support a conclusion on safety.[1]

A separate precaution notes that NGF is expressed within the heart and vasculature, and that the long-term effects of reduced NGF in dogs with cardiac disease are unknown.[1] An additional precaution notes that primates receiving high doses of anti-NGF monoclonal antibodies had anatomical changes in postganglionic cell bodies (reduced size and number of neurons), with normalization after discontinuation.[1]

Contraindications and reproductive safety

Bedinvetmab must not be administered to breeding, pregnant, or lactating dogs. The label notes that IgG antibodies such as Librela can cross the placental blood barrier and be excreted in milk, and that fetal abnormalities, increased rates of stillbirths, and increased postpartum fetal mortality have been observed in rodents and primates receiving anti-NGF monoclonal antibodies.[1] The safety and effectiveness of Librela in dogs under 12 months of age has not been evaluated.[1]

Immunogenicity

Anti-drug antibodies (ADA) to bedinvetmab were detected in a minority of dogs in the field studies. In the US field study, ADA were confirmed on Day 84 in 1 of 135 Librela-treated dogs. In the EU field study, ADA were confirmed in 2 of 138 treated dogs. Among 82 dogs who continued monthly Librela treatment for an additional six months, ADA were confirmed in 2 additional dogs.[1] The clinical significance of ADA formation in terms of loss of efficacy was not formally characterized due to assay limitations.[1]

How this fits clinical practice

This section summarizes labeled safety information and published pharmacovigilance data for licensed practitioners. It is an evidence summary, not clinical guidance; dosing per the label is 0.5 mg/kg SC once monthly (per the label dosing table), and all prescribing decisions should be based on the current prescribing information and clinical judgment.

The neurological adverse events listed in the 2025 post-approval label update represent a meaningful addition to the product information. Practitioners using Librela should be aware of the label's neurological AE list, provide the client information sheet before each injection as required by the label, and counsel owners to contact their veterinarian if signs including balance problems, trouble walking, weakness, trouble standing, seizures, increased drinking, increased urination, or loss of bladder control occur.[1]

The precaution against concurrent NSAID use reflects an important pharmacological gap. In dogs receiving both Librela and NSAIDs — a common clinical situation given the OA context — the safety data are limited to a brief two-week laboratory study and the long-term interaction profile is not established by controlled trial data.[1]

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=bedinvetmab-librela-adverse-events-dogs

References

1. Zoetis Inc. Librela (bedinvetmab injection) Prescribing Information. NADA 141-562. DailyMed, updated February 2025. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=61c7b4e0-aab6-4cf5-8471-f94be438c758&type=display
2. U.S. Food and Drug Administration openFDA Animal and Veterinary Adverse Events API. Bedinvetmab adverse event query, data through April 2026. https://api.fda.gov/animalandveterinary/event.json?search=drug.active_ingredients.name:bedinvetmab&limit=10&sort=original_receive_date:desc
3. Michels GM, Honsberger NA, Walters RR, et al. A prospective, randomized, double-blind, placebo-controlled multisite, parallel-group field study in dogs with osteoarthritis conducted in the United States of America evaluating bedinvetmab, a canine anti-nerve growth factor monoclonal antibody. Vet Anaesth Analg. 2023;50(5):446-458. https://pubmed.ncbi.nlm.nih.gov/37541934/
4. Corral MJ, Moyaert H, Fernandes T, et al. A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis. Vet Anaesth Analg. 2021;48(6):943-955. https://pubmed.ncbi.nlm.nih.gov/34565678/

Changelog

• 2026-06-05: First published.

Related reads

• Tasipimidine (Tessie) for Noise Aversion and Separation Anxiety in Dogs